Seres Therapeutics to Host Microbiome R&D Event and Webcast on May 24, 2018
The event will feature presentations from Seres management and leading academic subject matter experts on the microbiome as a new therapeutic target, with a focus on the Seres pipeline and the opportunity for microbiome therapeutics to impact immune biology.
Guest speakers scheduled to present at the event include:
- Will Dere, M.D.,
University of Utah Health Sciences Center ; Seres board member Stephen Hanauer , M.D.,Northwestern University Feinberg School of Medicine Alan Moss , M.D.,Beth Israel Deaconess Medical Center Jennifer Wargo , M.D., M.M.Sc.,MD Anderson Cancer Center
A live audio webcast of the presentation and accompanying slides will be available under the “Investors and Media” section of Seres’ website. A replay of the presentation will become available approximately one hour after the event and will be archived for 21 days.
About Seres Therapeutics
View source version on businesswire.com: https://www.businesswire.com/news/home/20180517005192/en/
Source:
IR or PR Contact:
Seres
Therapeutics
Carlo Tanzi, Ph.D., 617-203-3467
Vice President,
Investor Relations and Corporate Communications
ctanzi@serestherapeutics.com